These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6140459)

  • 21. Antibodies to normal human melanocytes in vitiligo.
    Naughton GK; Eisinger M; Bystryn JC
    J Exp Med; 1983 Jul; 158(1):246-51. PubMed ID: 6345714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
    Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
    Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies in patients with vitiligo.
    Brostoff J
    Lancet; 1969 Jul; 2(7613):177-8. PubMed ID: 4183134
    [No Abstract]   [Full Text] [Related]  

  • 24. [Autoantibodies in vitiligo].
    Herz KC
    Med Klin; 1978 Oct; 73(43):3. PubMed ID: 713958
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytolytic antibodies to melanocytes in vitiligo.
    Cui J; Arita Y; Bystryn JC
    J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Symptomatic tapetoretinal degeneration in pigment disorders of the skin: approaches to understanding the pathomechanism and therapy].
    Krastel H; Anton-Lamprecht I; Alexandridis E; Tilgen W
    Fortschr Ophthalmol; 1985; 82(6):562-70. PubMed ID: 4093108
    [No Abstract]   [Full Text] [Related]  

  • 27. Elevated serum antimelanocyte antibody level in cerebriform intradermal nevus with vitiligo.
    Lee CH; Yu HS
    J Dermatol; 2004 Jul; 31(7):540-5. PubMed ID: 15492418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo.
    Kroon MW; Kemp EH; Wind BS; Krebbers G; Bos JD; Gawkrodger DJ; Wolkerstorfer A; van der Veen JP; Luiten RM
    J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1172-5. PubMed ID: 22404127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of melanocyte autoantigens reacting with autoantibodies in vitiligo patients by proteomics.
    Kim JY; Do JE; Ahn KJ; Noh S; Jee HJ; Oh SH
    J Dermatol Sci; 2011 Jun; 62(3):202-4. PubMed ID: 21524886
    [No Abstract]   [Full Text] [Related]  

  • 31. Autoantibodies as diagnostic and predictive markers of vitiligo.
    Kemp EH
    Autoimmunity; 2004 Jun; 37(4):287-90. PubMed ID: 15518043
    [No Abstract]   [Full Text] [Related]  

  • 32. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
    Li YL; Yu CL; Yu HS
    J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Antibodies to Melanocytes in Patients With Vitiligo Are Predictors of Disease Progression.
    Jimenez-Brito G; Garza-de-La-Peña E; Pérez-Romano B; Ruiz-Argüelles A
    Skinmed; 2016; 14(1):17-21. PubMed ID: 27072723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
    al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
    J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of antibodies to melanoma cells in vitiligo by 125I-labeled SpA antibody binding assay].
    Mori N; Shimada K; Satoh N; Nagao S; Iijima S; Kanzaki T
    Nihon Hifuka Gakkai Zasshi; 1986 Jul; 96(8):835-8. PubMed ID: 3784053
    [No Abstract]   [Full Text] [Related]  

  • 36. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of serum immunoglobulins concentrations and distributions in vitiligo patients.
    Li Y; Yang M; Zhang R; Liu W; Zhang K; Wen W; Yi L; Wang Q; Hao M; Yang H; Chang J; Li J
    Immunol Res; 2016 Dec; 64(5-6):1150-1156. PubMed ID: 27417998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopathogenesis of vitiligo.
    Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
    Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune mechanisms in vitiligo.
    Bystryn JC
    Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo.
    Austin LM; Boissy RE
    Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.